Latest news
Loading news…
Syntaxin
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Abingdon, Oxfordshire, United Kingdom Founded 2005 1001-5000 employees For Profit
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
Syntaxin was acquired by Ipsen in 2013 for $206M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
12
1 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 6
- Active products
- 3
- Patents granted
- 12
- Trademarks
- 1
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $8.82M
Company Info
- Founded
- 2005
- Employees
- 1001-5000
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 1
- HQ
- Abingdon, Oxfordshire, United Kingdom
- Region
- Europe, Middle East, and Africa (EMEA)
- Exit date
- Jul 15, 2013
Signals & Scores
- Heat score
- Low
- Trend (7d)
- -0.3
- Trend (30d)
- -1.4
- Trend (90d)
- -1.8
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Syntaxin
Loading news…
FAQs about Syntaxin
People who checked this page also checked these
Browse the full Acquirezy directory.